NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.81 +0.12 (+0.15%) GOLD FUTURES
2,397.60 +9.20 (+0.39%) DOW
37,779.77 +26.46 (+0.07%) Bitcoin GBP
50,851.85 +1,621.27 (+3.29%)
Novartis AG (NOVNN.MX)
| Previous close | 1,719.29 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 1,719.29 - 1,719.29 |
| 52-week range | 1,719.29 - 1,719.29 |
| Volume | |
| Avg. volume | 50 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy o
- GlobeNewswire
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement activation is a key driver of glomerular inflammation in IgAN3,4There is a need for effective, targeted therapies for IgAN2,5; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure
Yahoo FinanceAntitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.
